FDA approved Ionis’ Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
FDA approved Ionis’ Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.